7/30/2009

GlaxoSmithKline withdrew its application in Europe for mepolizumab, an experimental treatment for hypereosinophilic syndrome, a blood disorder. The company, which wants to market the drug as Bosatria, said authorities would have requested additional data to prove the product's benefits.

Full Story:
Reuters

Related Summaries